Doctors say the drugs that treat diabetes and obesity are life savers ... Responding to complaints about high costs, Eli Lilly, maker of Zepbound, says in part: "Obesity is a chronic, progressive ...

For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots: Mounjaro, ...

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist ...

but taking into account the huge need there would probably continue to be supply constraints until we had an oral medicine with an injectable-like efficacy,” President of Lilly Diabetes and ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

Lilly yesterday announced the next component in the ‘beyond the pill’ strategy it is constructing for diabetes, a new alliance with digital health company Rimidi.

2024 revenue forecast: $45.0 billion (+32% YoY), below the $45.50 billion consensus. 2025 revenue guidance: $58.0 billion to $61.0 billion, driven by new medicines and global expansions.

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly ... year growing share in diabetes. We're now the NBRx ...

Eli Lilly’s pursuit of privately owned Scorpion is the latest example of its strategy of redistributing the huge windfall from its blockbuster diabetes and obesity drugs Mounjaro and Zepbound ...